跳至主要内容
临床试验/NCT04100265
NCT04100265终止不适用

ANTERO-5: A Clinical Investigation of Gastric Motility in Adult Patients at Risk to Develop Postoperative Ileus Following Colorectal Surgery

Universitaire Ziekenhuizen KU Leuven2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2019年10月16日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
5
试验地点
2
主要终点
Feasibility (composite endpoint)

研究概览

简要总结

A monocenter, non-randomized interventional investigation in 3 panels of adult patients undergoing elective colorectal surgery who are at risk to develop postoperative ileus.

The feasibility to use the VIPUN Gastric Monitoring System prototype 0.3 will be explored in this population for the first time.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed Informed Consent
  • At least 18 years old
  • BMI between and including 18 and 30
  • Understand and able to read Dutch
  • Planned to undergo elective colorectal surgery

排除标准

  • Known history of documented gastroparesis
  • Known history of functional dyspepsia
  • Known / suspected current use of illicit drugs
  • Known psychiatric or neurological illness
  • Any prior gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator
  • Known history of heart or vascular diseases like irregular heartbeats, angina or heart attack
  • Nasopharyngeal surgery in the last 30 days
  • Suspected basal skull fracture or severe maxillofacial trauma
  • Known history of thermal or chemical injury to upper respiratory tract or esophagus
  • Current esophageal or nasopharyngeal obstruction
  • Known coagulopathy
  • Known esophageal varices

结局指标

主要结局

Feasibility (composite endpoint)

时间窗: Day 1 - Day 14

Composite endpoint comprising: procedural success (absence of protocol deviations with regard to motility measurement), tolerability of the device (non-validated questionnaire on nasopharyngeal discomfort and the incidence of intolerance resulting in early removal of the investigational device) and device-related safety (incidence of adverse device effects related to the use of the device).

次要结局

  • Evolution postoperative ileus - staff reported(Day 1 until completion study procedures (maximum 14 days).)
  • In hospital quality of life (EQ-5D-3L questionnaire)(Day 1 until completion study procedures (maximum 14 days))
  • Abdominal bloating severity(Day 1 until completion study procedures (maximum 14 days))
  • Abdominal pain severity(Day 1 until completion study procedures (maximum 14 days))
  • Abdominal discomfort severity(Day 1 until completion study procedures (maximum 14 days))
  • Gastric motility(Day 1 until termination motility recording (maximum 48 hours))
  • Nausea severity(Day 1 until completion study procedures (maximum 14 days))
  • Device performance(Day 1 until removal of device, no later than Day 14)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验